期刊名称：EXPERT REVIEW OF CLINICAL PHARMACOLOGY ISSN： 1751-2433 出版频率： Monthly 出版社： TAYLOR & FRANCIS LTD, 2-4 PARK SQUARE, MILTON PARK, ABINGDON, England, OXON, OX14 4RN   出版社网址： http://www.tandfonline.com/ 期刊网址： http://www.tandfonline.com/loi/ierj20 影响因子： 5.05 主题范畴： PHARMACOLOGY & PHARMACY 变更情况： 期刊简介(About the journal)    投稿须知(Instructions to Authors)    编辑部信息(Editorial Board)    About the journal . 1751-2433 (Print), 1751-2441 (Online) Aims & scope Advances in drug development technologies are yielding innovative new therapies, from potentially lifesaving medicines to lifestyle products. In recent years, however, the cost of developing new drugs has soared, and concerns over drug resistance and pharmacoeconomics have come to the fore. Adverse reactions experienced at the clinical trial level serve as a constant reminder of the importance of rigorous safety and toxicity testing. Furthermore the advent of pharmacogenomics and ‘individualized’ approaches to therapy will demand a fresh approach to drug evaluation and healthcare delivery. Clinical Pharmacology provides an essential role in integrating the expertise of all of the specialists and players who are active in meeting such challenges in modern biomedical practice. Expert Review of Clinical Pharmacology (ISSN 1751-2433) provides a forum for informed debate and critical analysis of all aspects of safety, tolerability, efficacy and therapeutic applications, in addition to covering toxicity issues, adverse reactions, pharmacoeconomics and societal issues. Coverage includes: • ADME studies and PK/PD modeling • Novel clinical trial design and conduct • Toxicity and carcinogenesis • Adverse effects/reactions, drug–drug and drug–disease interactions • Pharmacogenetics, genomics and the incorporation of new biomarkers in drug development and clinical practice • Translational medicine • Pharmacoepidemiology, risk management and pharmacovigilance • Pharmacotherapy in specific patient groups, such as children, women, the immunocompromised • Pharmacology and ethnicity • Impact on quality of life and pharmacoeconomic issues • Regulation of drug development and marketing • Epidemiology and biostatistics Expert Review of Clinical Pharmacology bridges the gap between the medical profession, clinical research and the pharmaceutical industry, providing clinical and pharmaceutical researchers, drug development specialists, physicians and other healthcare professionals with the key information they need to assist in the progress of pharmacological therapy. All reviews are subject to rigorous peer review in association with our independent panel of Editorial Board members, representing the key experts in their pharmacological specialties. Subjects covered by this journal Bioscience; Clinical Pharmacology & Therapeutics; Medicine; Medicine, Dentistry, Nursing & Allied Health; Pharmaceutical Medicine; Pharmacology Abstracting & indexing Expert Review of Clinical Pharmacology is included in the following abstracting and indexing services: Chemical Abstracts; EMBASE/Excerpta Medica; MEDLINE/Index Medicus; Scopus.   2014 Impact Factor: 2.180 © 2014 Thomson Reuters, Journal Citation Reports® Instructions to Authors If you are preparing a manuscript to submit to Expert Review of Clinical Pharmacology please visit the following links: Instructions for drug profiles: http://www.tandf.co.uk/journals/authors/healthcare/IERJ-Drug-Profile-Author-Guidelines.pdf Instructions for expert reviews: http://www.tandf.co.uk/journals/authors/healthcare/IERJ-Expert-Reviews-Author-Guidelines.pdf   To explore our journals portfolio, visit http://www.tandfonline.com/, and for more author resources, visit our Author Services website. Visit our Author Services website for further resources and guides to the complete publication process and beyond. Instructions to Authors IERJ-Drug-Profile-Author-Guidelines.pdf Editorial Board Editor in Chief Kaitin K, Tufts University, USA Associate Editors Jahangir A, Mayo Clinic, MN, USA Postma M, Groningen Univeristy, The Netherlands Stingl JC, University of Ulm, Germany Van Den Anker J, GWU School of Medicine and Health Sciences Wang X, Fudan University, China Editorial Advisory Panel Alderman CP, Repatriation Gen. Hosp., Australia Bednarczyk E, SUNY Buffalo, NY, USA Cheung BMY, University of Hong Kong, China Cohen J, Tufts University, USA Dreisbach AW, Tulane University, USA Hay J, Univ. of Southern California, USA Herings R, PHARMO Institute, The Netherlands Hoffman P, University of Colorado, USA Huang S-M, CDER, FDA, USA Issa A, University of Houston, USA Levy HB, HbL PharmaConsulting, MO, USA Ma Q, SUNY Buffalo, NY, USA Mangoni AA, Flinders Medical Centre, Australia Mentzer D, Paul Ehrlich Institute, Germany Niemi M, Helsinki Univ. Central Hospital, Finland Ohashi K, Oita University. Oita, Japan Olech E, Oklahoma Medical Research, OK, USA Patsalos P, Institute of Neurology, UK Slaughter R, Wayne State University, USA Waldman SA, Thomas Jefferson University, PA, USA Waring S, York Hospital, UK Khurana V, Insys Therapeutics Inc., AZ, USA